These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 31471396)
1. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern. Kim HN; Woo HY; DO SI; Kim HS In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396 [TBL] [Abstract][Full Text] [Related]
3. Na K; Sung JY; Kim HS Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446 [TBL] [Abstract][Full Text] [Related]
4. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
5. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067 [TBL] [Abstract][Full Text] [Related]
6. Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries. Anglesio MS; O'Neill CJ; Senz J; Gilks CB; McCluggage WG Histopathology; 2017 Dec; 71(6):1014-1017. PubMed ID: 28746984 [No Abstract] [Full Text] [Related]
7. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma. Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306 [TBL] [Abstract][Full Text] [Related]
8. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341 [TBL] [Abstract][Full Text] [Related]
9. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin. Morency E; Leitao MM; Soslow RA Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225 [TBL] [Abstract][Full Text] [Related]
10. The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma. Soong TR; Howitt BE; Horowitz N; Nucci MR; Crum CP Gynecol Oncol; 2019 Feb; 152(2):426-433. PubMed ID: 30503267 [TBL] [Abstract][Full Text] [Related]
11. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522 [TBL] [Abstract][Full Text] [Related]
12. The genomic trajectory of ovarian high-grade serous carcinoma can be observed in STIC lesions. Cheng Z; Ennis DP; Lu B; Mirza HB; Sokota C; Kaur B; Singh N; Le Saux O; Russo G; Giannone G; Tookman LA; Krell J; Barnes C; McDermott J; McNeish IA J Pathol; 2024 Sep; 264(1):42-54. PubMed ID: 38956451 [TBL] [Abstract][Full Text] [Related]
13. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714 [TBL] [Abstract][Full Text] [Related]
14. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum]. Škapa P; Dundr P Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446 [TBL] [Abstract][Full Text] [Related]
15. Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. Novak M; Lester J; Karst AM; Parkash V; Hirsch MS; Crum CP; Karlan BY; Drapkin R Gynecol Oncol; 2015 Oct; 139(1):104-11. PubMed ID: 26206555 [TBL] [Abstract][Full Text] [Related]
16. Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging. Singh N; Faruqi A; Kommoss F; McCluggage WG; Trevisan G; Senz J; Lum A; Gilks CB; Anglesio M Mod Pathol; 2018 Apr; 31(4):652-659. PubMed ID: 29148539 [TBL] [Abstract][Full Text] [Related]
17. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388 [TBL] [Abstract][Full Text] [Related]
18. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma? Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721 [TBL] [Abstract][Full Text] [Related]